Necroptosis has been recognized in heart failure (HF). In this study, we investigated detailed necroptotic signalling in infarcted and non-infarcted areas separately and its mechanistic link with main features of HF. Post-infarction HF in rats was induced by left coronary occlusion (60 minutes) followed by 42-day reperfusion. Heart function was assessed echocardiographically. Molecular signalling and proposed mechanisms (oxidative stress, collagen deposition and inflammation) were investigated in whole hearts and in subcellular fractions when appropriate. In post-infarction failing hearts, TNF and pSer229-RIP3 levels were comparably increased in both infarcted and non-infarcted areas. Its cytotoxic downstream molecule p-MLKL, indicating necroptosis execution, was detected in infarcted area. In non-infarcted area, despite increased pSer229-RIP3, p-MLKL was present in neither whole cells nor the cell membrane known to be associated with necroptosis execution. Likewise, increased membrane lipoperoxidation and NOX2 levels unlikely promoted pro-necroptotic environment in non-infarcted area. Collagen deposition and the inflammatory csp-1-IL-1β axis were active in both areas of failing hearts, while being more pronounced in infarcted tissue. Although apoptotic proteins were differently expressed in infarcted and non-infarcted tissue, apoptosis was found to play an insignificant role. p-MLKL-driven necroptosis and inflammation while inflammation only (without necroptotic cell death) seem to underlie fibrotic healing and progressive injury in infarcted and non-infarcted areas of failing hearts, respectively. Upregulation of pSer229-RIP3 in both HF areas suggests that this kinase, associated with both necroptosis and inflammation, is likely to play a dual role in HF progression.

Faculty of Pharmacy Department of Pharmacology and Toxicology Comenius University in Bratislava Bratislava Slovak Republic

Institute of Physiology of the Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Pasumarthi KB, Field LJ. Cardiomyocyte cell cycle regulation. Circ Res. 2002;90:1044‐1054. PubMed

Luedde M, Lutz M, Carter N, et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res. 2014;103:206‐216. PubMed

Zhang T, Zhang Y, Cui M, et al. CaMKII is a RIP3 substrate mediating ischemia‐ and oxidative stress‐induced myocardial necroptosis. Nat Med. 2016;22:175‐182. PubMed

Li L, Chen Y, Doan J, Murray J, Molkentin JD, Liu Q. Transforming growth factor beta‐activated kinase 1 signaling pathway critically regulates myocardial survival and remodeling. Circulation. 2014;130:2162‐2172. PubMed PMC

Szobi A, Goncalvesova E, Varga ZV, et al. Analysis of necroptotic proteins in failing human hearts. J Transl Med. 2017;15:86. PubMed PMC

Oerlemans MI, Liu J, Arslan F, et al. Inhibition of RIP1‐dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia‐reperfusion in vivo. Basic Res Cardiol. 2012;107:270. PubMed

Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4:313‐321. PubMed PMC

He S, Wang L, Miao L, et al. Receptor interacting protein kinase‐3 determines cellular necrotic response to TNF‐alpha. Cell. 2009;137:1100‐1111. PubMed

Zhang DW, Shao J, Lin J, et al. RIP3, an energy metabolism regulator that switches TNF‐induced cell death from apoptosis to necrosis. Science. 2009;325:332‐336. PubMed

Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain‐like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:213‐227. PubMed

Cho YS, Challa S, Moquin D, et al. Phosphorylation‐driven assembly of the RIP1‐RIP3 complex regulates programmed necrosis and virus‐induced inflammation. Cell. 2009;137:1112‐1123. PubMed PMC

Huang D, Zheng X, Wang ZA, et al. The MLKL channel in necroptosis is an octamer formed by tetramers in a dyadic process. Mol Cell Biol. 2017;37. PubMed PMC

Ros U, Pena‐Blanco A, Hanggi K, et al. Necroptosis execution is mediated by plasma membrane nanopores independent of calcium. Cell Rep. 2017;19:175‐187. PubMed PMC

Cai Z, Jitkaew S, Zhao J, et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF‐induced necroptosis. Nat Cell Biol. 2014;16:55‐65. PubMed PMC

Cai Z, Liu ZG. Execution of RIPK3‐regulated necrosis. Mol Cell Oncol. 2014;1:e960759. PubMed PMC

Conos SA, Chen KW, De Nardo D, et al. Active MLKL triggers the NLRP3 inflammasome in a cell‐intrinsic manner. Proc Natl Acad Sci USA. 2017;114:E961‐E969. PubMed PMC

Kang TB, Yang SH, Toth B, Kovalenko A, Wallach D. Caspase‐8 blocks kinase RIPK3‐mediated activation of the NLRP3 inflammasome. Immunity. 2013;38:27‐40. PubMed

Vince JE, Wong WW, Gentle I, et al. Inhibitor of apoptosis proteins limit RIP3 kinase‐dependent interleukin‐1 activation. Immunity. 2012;36:215‐227. PubMed

Hrdlicka J, Neckar J, Papousek F, Vasinova J, Alanova P, Kolar F. Beneficial effect of continuous normobaric hypoxia on ventricular dilatation in rats with post‐infarction heart failure. Physiol Res. 2016;65:867‐870. PubMed

da Silva CM, Spinelli E, Rodrigues SV. Fast and sensitive collagen quantification by alkaline hydrolysis/hydroxyproline assay. Food Chem. 2015;173:619‐623. PubMed

Moritz CP. Tubulin or not Tubulin: heading toward total protein staining as loading control in western blots. Proteomics. 2017;17:1600189. PubMed

Kinoshita E, Kinoshita‐Kikuta E, Takiyama K, Koike T. Phosphate‐binding tag, a new tool to visualize phosphorylated proteins. Mol Cell Proteomics. 2006;5:749‐757. PubMed

Kinoshita E, Kinoshita‐Kikuta E. Improved Phos‐tag SDS‐PAGE under neutral pH conditions for advanced protein phosphorylation profiling. Proteomics. 2011;11:319‐323. PubMed

Szobi A, Farkasova‐Ledvenyiova V, Lichy M, et al. Cardioprotection of ischaemic preconditioning is associated with inhibition of translocation of MLKL within the plasma membrane. J Cell Mol Med. 2018. PubMed PMC

Wang H, Sun L, Su L, et al. Mixed lineage kinase domain‐like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell. 2014;54:133‐146. PubMed

Adameova A, Goncalvesova E, Szobi A, Dhalla NS. Necroptotic cell death in failing heart: relevance and proposed mechanisms. Heart Fail Rev. 2016;21:213‐221. PubMed

Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112‐119. PubMed

Sedger LM, McDermott MF. TNF and TNF‐receptors: from mediators of cell death and inflammation to therapeutic giants ‐ past, present and future. Cytokine Growth Factor Rev. 2014;25:453‐472. PubMed

Lawlor KE, Khan N, Mildenhall A, et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat Commun. 2015;6:6282. PubMed PMC

Kleikers PW, Wingler K, Hermans JJ, et al. NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury. J Mol Med (Berl). 2012;90:1391‐1406. PubMed

Zhang M, Perino A, Ghigo A, Hirsch E, Shah AM. NADPH oxidases in heart failure: poachers or gamekeepers? Antioxid Redox Signal. 2013;18:1024‐1041. PubMed PMC

Wong WW, Vince JE, Lalaoui N, et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1‐ and RIPK3‐dependent manner. Blood. 2014;123:2562‐2572. PubMed

Chiong M, Wang ZV, Pedrozo Z, et al. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis. 2011;2:e244. PubMed PMC

Adameova A, Hrdlicka J, Szobi A, et al. Evidence of necroptosis in hearts subjected to various forms of ischemic insults. Can J Physiol Pharmacol. 2017;95:1163‐1169. PubMed

Moreno‐Gonzalez G, Vandenabeele P, Krysko DV. Necroptosis: a novel cell death modality and its potential relevance for critical care medicine. Am J Respir Crit Care Med. 2016;194:415‐428. PubMed

Galluzzi L, Kepp O, Chan FK, Kroemer G. Necroptosis: mechanisms and relevance to disease. Annu Rev Pathol. 2017;12:103‐130. PubMed PMC

Chen W, Zhou Z, Li L, et al. Diverse sequence determinants control human and mouse receptor interacting protein 3 (RIP3) and mixed lineage kinase domain‐like (MLKL) interaction in necroptotic signaling. J Biol Chem. 2013;288:16247‐16261. PubMed PMC

Liu YR, Xu HM. Protective effect of necrostatin‐1 on myocardial tissue in rats with acute myocardial infarction. Genet Mol Res. 2016;15 10.4238/gmr.15027298 PubMed DOI

Koshinuma S, Miyamae M, Kaneda K, Kotani J, Figueredo VM. Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia‐reperfusion injury. J Anesth. 2014;28:235‐241. PubMed

Zhang A, Mao X, Li L, et al. Necrostatin‐1 inhibits Hmgb1‐IL‐23/IL‐17 pathway and attenuates cardiac ischemia reperfusion injury. Transpl Int. 2014;27:1077‐1085. PubMed

Qin D, Wang X, Li Y, et al. MicroRNA‐223‐5p and ‐3p cooperatively suppress necroptosis in ischemic/reperfused hearts. J Biol Chem. 2016;291:20247‐20259. PubMed PMC

Smith CC, Davidson SM, Lim SY, Simpkin JC, Hothersall JS, Yellon DM. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther. 2007;21:227‐233. PubMed

Koudstaal S, Oerlemans MI, Van der Spoel TI, et al. Necrostatin‐1 alleviates reperfusion injury following acute myocardial infarction in pigs. Eur J Clin Invest. 2015;45:150‐159. PubMed

Moujalled DM, Cook WD, Okamoto T, et al. TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1. Cell Death Dis. 2013;4:e465. PubMed PMC

Chen X, Li W, Ren J, et al. Translocation of mixed lineage kinase domain‐like protein to plasma membrane leads to necrotic cell death. Cell Res. 2014;24:105‐121. PubMed PMC

Bujak M, Dobaczewski M, Chatila K, et al. Interleukin‐1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol. 2008;173:57‐67. PubMed PMC

Orn S, Ueland T, Manhenke C, et al. Increased interleukin‐1beta levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Intern Med. 2012;272:267‐276. PubMed

Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation. 1998;98:149‐156. PubMed

Zhu K, Liang W, Ma Z, et al. Necroptosis promotes cell‐autonomous activation of proinflammatory cytokine gene expression. Cell Death Dis. 2018;9:500. PubMed PMC

Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial‐to‐mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952‐961. PubMed

Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7:803‐815. PubMed

Perez L, Munoz‐Durango N, Riedel CA, et al. Endothelial‐to‐mesenchymal transition: Cytokine‐mediated pathways that determine endothelial fibrosis under inflammatory conditions. Cytokine Growth Factor Rev. 2017;33:41‐54. PubMed

Maleszewska M, Moonen JR, Huijkman N, van de Sluis B, Krenning G, Harmsen MC. IL‐1beta and TGFbeta2 synergistically induce endothelial to mesenchymal transition in an NFkappaB‐dependent manner. Immunobiology. 2013;218:443‐454. PubMed

Rieder F, Kessler SP, West GA, et al. Inflammation‐induced endothelial‐to‐mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol. 2011;179:2660‐2673. PubMed PMC

Ma KL, Liu J, Ni J, et al. Inflammatory stress exacerbates the progression of cardiac fibrosis in high‐fat‐fed apolipoprotein E knockout mice via endothelial‐mesenchymal transition. Int J Med Sci. 2013;10:420‐426. PubMed PMC

Widyantoro B, Emoto N, Nakayama K, et al. Endothelial cell‐derived endothelin‐1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial‐to‐mesenchymal transition. Circulation. 2010;121:2407‐2418. PubMed

Kovacic JC, Mercader N, Torres M, Boehm M, Fuster V. Epithelial‐to‐mesenchymal and endothelial‐to‐mesenchymal transition: from cardiovascular development to disease. Circulation. 2012;125:1795‐1808. PubMed PMC

Jose Corbalan J, Vatner DE, Vatner SF. Myocardial apoptosis in heart disease: does the emperor have clothes? Basic Res Cardiol. 2016;111:31. PubMed

Guo X, Yin H, Li L, et al. Cardioprotective role of tumor necrosis factor receptor‐associated factor 2 by suppressing apoptosis and necroptosis. Circulation. 2017;136:729‐742. PubMed PMC

Inserte J, Cardona M, Poncelas‐Nozal M, et al. Studies on the role of apoptosis after transient myocardial ischemia: genetic deletion of the executioner caspases‐3 and ‐7 does not limit infarct size and ventricular remodeling. Basic Res Cardiol. 2016;111:18. PubMed

Lesauskaite V, Epistolato MC, Ivanoviene L, Tanganelli P. Apoptosis of cardiomyocytes in explanted and transplanted hearts. Comparison of results from in situ TUNEL, ISEL, and ISOL reactions. Am J Clin Pathol. 2004;121:108‐116. PubMed

de Boer RA, van Veldhuisen DJ, van der Wijk J, et al. Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. J Card Fail. 2000;6:330‐337. PubMed

Kuranaga E, Miura M. Nonapoptotic functions of caspases: caspases as regulatory molecules for immunity and cell‐fate determination. Trends Cell Biol. 2007;17:135‐144. PubMed

White K, Arama E, Hardwick JM. Controlling caspase activity in life and death. PLoS Genet. 2017;13:e1006545. PubMed PMC

Necrosis-like cell death modes in heart failure: the influence of aetiology and the effects of RIP3 inhibition

Sixty Years of Heart Research in the Institute of Physiology of the Czech Academy of Sciences

Analysis of Signaling Pathways of Necroptotic and Pyroptotic Cell Death in the Hearts of Rats With Type 2 Diabetes Mellitus

Hydrogen sulfide protects against ischemic heart failure by inhibiting RIP1/RIP3/MLKL-mediated necroptosis

Programmed Cell Death in the Left and Right Ventricle of the Late Phase of Post-Infarction Heart Failure